TY  - BOOK
AU  - Barac, Ana
TI  - Left-Ventricular Function After 3 Months of Sacubitril-Valsartan in Acute Decompensated Heart Failure
SN  - 1937-5387
PY  - 2021///
KW  - *Aminobutyrates/tu [Therapeutic Use]
KW  - *Angiotensin II Type 1 Receptor Blockers/tu [Therapeutic Use]
KW  - *Angiotensin-Converting Enzyme Inhibitors/tu [Therapeutic Use]
KW  - *Biphenyl Compounds/tu [Therapeutic Use]
KW  - *Heart Failure/dt [Drug Therapy]
KW  - *Protease Inhibitors/tu [Therapeutic Use]
KW  - *Valsartan/tu [Therapeutic Use]
KW  - *Ventricular Function, Left/de [Drug Effects]
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Aminobutyrates/ae [Adverse Effects]
KW  - Angiotensin II Type 1 Receptor Blockers/ae [Adverse Effects]
KW  - Angiotensin-Converting Enzyme Inhibitors/ae [Adverse Effects]
KW  - Biphenyl Compounds/ae [Adverse Effects]
KW  - Croatia
KW  - Drug Combinations
KW  - Echocardiography
KW  - Female
KW  - Heart Failure/dg [Diagnostic Imaging]
KW  - Heart Failure/pp [Physiopathology]
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Neprilysin/ai [Antagonists & Inhibitors]
KW  - Prospective Studies
KW  - Protease Inhibitors/ae [Adverse Effects]
KW  - Recovery of Function
KW  - Stroke Volume/de [Drug Effects]
KW  - Time Factors
KW  - Treatment Outcome
KW  - Valsartan/ae [Adverse Effects]
KW  - MedStar Heart & Vascular Institute
KW  - Journal Article
N2  - There is limited data on the effect of sacubitril-valsartan on the echocardiographic parameters in acute decompensated heart failure (ADHF). We prospectively enrolled 68 consecutive patients with ADHF who received sacubitril-valsartan (N = 34, S/V group) or angiotensin inhibition-based therapy (N = 34, ACEi/ARB group). Two-dimensional echocardiography with speckle tracking (2D-STE) was performed at baseline and after 3 months of treatment. Changes in 2D-STE parameters, including global longitudinal strain (GLS), were compared between the groups by t test and ANCOVA. Baseline characteristics were similar between the groups. Following 3 months of treatment, LVEF and GLS significantly improved in the S/V group (mean LVEF from 27 to 34.5% and GLS from - 6.6 to - 9.4%) but not in ACEi/ARB group. The improvement in LVEF and GLS was more prominent in patients with non-ischemic cardiomyopathy. In patients with ADHF 3-month treatment with sacubitril-valsartan, compared to guideline directed medical therapy without sacubitril, improves LVEF and GLS. Graphical Abstract A typical change in GLS in a patient with acute decompensated heart failure after 3 months of sacubitril-valsartan
UR  - https://dx.doi.org/10.1007/s12265-020-10041-4
ER  -